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Bernie O’Brien died tragically on the morning of
February 13, while out jogging. He was 44 years
old.
After completing a ﬁrst degree in economics and
an MSc in Health Economics at the University of
York, Bernie’s early career was as a research fellow
in the Health Economics Research Group at Brunel
University. His research baptism was in the team
that undertook the pioneering economic evaluation
of the heart transplant programs in the UK. He
developed an interest in the economic analysis of
clinical risk, and obtained his PhD at Brunel with a
thesis on that topic. After 8 years at Brunel, Bernie
moved to Canada accepting a post at McMaster
University where his career ﬂourished. He devel-
oped a strong team of researchers in the Center for
Evaluation of Medicines at St Joseph’s Hospital,
and with them made important contributions to the
empiric basis of cost-effectiveness analysis and to its
methodological development. His CV includes
more than 140 journal articles, in addition to mon-
ographs, reports, contributions to books, confer-
ence abstracts, etc. Amongst the awards he won
were the following: from the Society for Medical
Decision Making for “Outstanding Paper by a
Young Investigator” (1995); from ISPOR, the
ISPOR Research Excellence Award for Methodol-
ogy Science (in 2000 with Andy Willan, and again
in 2002); from the MRC/Pharmaceutical Manufac-
turer’s Association of Canada, a Career Award in
Health Sciences (1995–2000), and from the Cana-
dian Institutes of Health Research, a Senior Inves-
tigator Award (2002–2007).
This brief summary clearly shows that with
Bernie’s death the world lost a ﬁrst-rate researcher,
and an internationally respected academic and
teacher. When one recalls the details of his research,
his contribution becomes all the more impressive,
not least in the range of topics on which he worked.
He was not an academic who had discovered a
small area of comparative advantage and who kept
mining that narrow seam of research. Rather, his
research covered a remarkably broad range of
applied topics and methodological issues. He under-
took trial-based and modeling studies in ﬁelds as
diverse as deep-vein thrombosis, helicobacter
pylori, implantable deﬁbrillators, atrial ﬁbrillation,
Alzheimer’s disease, and depression. He made sig-
niﬁcant contributions to the development of the
methodology of economic evaluation, particularly
in relation to the application of statistical methods
in cost-effectiveness analysis and to the valuation of
health outcomes, in terms of both contingent valu-
ation and “utility” measurement.
Nevertheless, even these details fail to capture the
reasons for the profound loss felt by his current and
past colleagues, by his friends, and by the many
people who came into contact with him as a con-
sultant, a lecturer, a teacher, or a mentor. Bernie
made the working lives of all these people more
interesting, more stimulating, more challenging,
and more fun. He used jokes, cartoons, and catchy
titles (including some terrible puns) to help make
important points and to grab people’s attention.
He relished the challenges that he met in the
application of economic evaluation—the “Franken-
stein’s monster” that he helped both to create and to
tame. Whereas he enjoyed an academic argument,
and would intellectually spar and parry with the
next man, in the end he was concerned that health
economics should be of practical value. He never
lost sight of the fact that the main role of economic
evaluation was to help doctors and health agencies,
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facing inevitable resource constraints, to make cost-
effective choices under conditions of uncertainty.
His research group had just begun working on a
major program of policy-relevant health-technology
assessment and economic evaluation for the
Ontario Ministry of Health.
The concept of a “fair innings” is current in
health economics as we grapple with the trade-offs
between efﬁciency and equity. Bernie’s untimely
death reminds us that life is not distributed fairly,
but that some make a disproportionate impact in a
relatively short span. What is more, his inﬂuence
and indirect impact will continue. Bernie had a
wonderful ability to encourage and mentor young
researchers. He shared with them his intellectual
excitement about new ideas or new ways of think-
ing, and showed them that health economics could
be professionally rewarding, occasionally even
ﬁnancially rewarding, and almost always fun. A
quick review of his coauthors shows that Bernie has
inﬂuenced an impressive cohort of researchers. Sev-
eral of these individuals have already developed into
signiﬁcant health economists in their own right and
others will no doubt follow as an ongoing tribute to
his inﬂuence.
Nevertheless, the great loss we feel, as colleagues,
shrinks into insigniﬁcance in comparison with the
loss that must be felt by his wife, daughters, and
close family. We only hope that they can take some
consolation in realizing in what exceptionally high
esteem and affection Bernie was held by so many
professional colleagues and friends.
In recognition of his accomplishments, The
ISPOR Bernie J. O’Brien New Investigator Award
was established in 2004 to honor the long-stand-
ing commitment of Bernie J. O’Brien, PhD, to
training and mentoring new scientists in the ﬁelds
of outcomes research and pharmacoeconomics.
For further details of this award, please contact
ISPOR.
